Lyophilized from a 0.2 μm filtered solution of PBS, Ph7.4, 0.03% Proclin 300
12 months from date of receipt, -20 to -70 °C as supplied
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells and thereby, allows the immune system to destroy them. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. Pembrolizumab was approved for medical use in the United States in 2014. The product is produced from serum of some rabbits immunized with Pembrolizumab. It is specific for Pembrolizumab. This antibody serves as an excellent positive control for Pembrolizumab immunogenicity (ADA) assays.
Dot blot result of Anti-Pembrolizumab Rabbit pAb
Lane 1: Fab of Pembrolizumab
Lane 2: Pembrolizumab
Lane 3: Human total IgG
Lane 4: Human IgG4
Primary antibody: Anti-Pembrolizumab Rabbit pAb at 1/500 dilution
Secondary antibody: Goat Anti-Rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
(This blot was developed with high sensitivity substrate)
ELISA binding of Anti-Pembrolizumab Rabbit pAb with Pembrolizumab and
human lgG /lgG4.
Coating antigen: Pembrolizumab, Human lgG, Human lgG 4, all coat with 0.1 ug/ml.
Anti-Pembrolizumab Rabbit pAb, dilution starts from 1000 ng/ml.
EC50=13.89 ng/ml.
您现在的位置：